MEDLINE/PubMed Journal Browser Search

Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

Title: [Expressions and clinical significances of paired box gene 2 and cyclin D1 in advanced ovarian serous carcinoma].
Author: Song Y, Zuo J, Huang X, Shen GH, Liu XY, Zhang X.
Journal: Zhonghua Zhong Liu Za Zhi; 2017 Dec 23; 39(12):891-895. PubMed ID: 29262504.
Abstract:
Objective: To investigate the expressions and clinical significances of paired box gene 2 (Pax2) and cyclin D1 protein in advanced ovarian serous carcinoma. Methods: From January 2003 to December 2013, the pathologic tissues of 202 patients with advanced ovarian serous cancer (Ⅲ-Ⅳ) who underwent initial cytoreductive surgery were collected. The expressions of Pax2 and cyclin D1 protein were detected by immunohistochemistry in tissue microarray. The relationships of their expressions with the clinicopathological features and prognosis of the patients were analyzed. Results: The positive rate of Pax2 protein expression of the 202 patients with ovarian serous adenocarcinoma was 24.8% (50/202) and that of cyclin D1 was 25.2% (51/202). The expressions of Pax2 and cyclin D1 were not significantly related with age, clinical stage and pathological grade of ovarian serous adenocarcinoma patients (P>0.05). The median overall survival (OS) time of Pax2-negative patients was 53 months and the progression-free survival (PFS) time was 29 months. The median OS time of Pax2-positive patients was 66 months and PFS time was 33 months, the OS of Pax2-negative patients was significant different from that of Pax2-positive patients (χ(2)=4.06, P=0.04). The median PFS time of Pax2-negative patients was not significant different from that of Pax2-positive patients (χ(2)=2.43, P=0.11). The median OS time of cyclin D1-negative patients was 62 months and PFS time was 30 months. The median OS time of cyclin D1-positive patients was 48 months and PFS time was 22 months. The median OS time of cyclin D1-negative patients was significantly different from that of cyclin D1-positive patients (χ(2)=4.71, P=0.03), while the median PFS time of cyclin D1-negative patients was marginally different from that of cyclin D1-positive patients (χ(2)=0.59, P=0.41). Multivariate analysis showed that the expression of Pax2 was an independent factor of the prognosis for patients with ovarian serous adenocarcinoma (RR=0.597, 95% CI 0.371-0.962, P<0.034). Conclusion: The expressions of Pax2 and cyclin D1 are associated with the prognosis of patients with advanced ovarian serous adenocarcinoma while Pax2 is an independent prognostic factor. 目的： 探讨配对盒基因2(Pax2)和细胞周期蛋白D1 (cyclin D1)在晚期卵巢浆液性腺癌中的表达及临床意义。 方法： 2003年1月至2013年12月间行初治卵巢癌肿瘤细胞减灭术的晚期(Ⅲ～Ⅳ期)卵巢浆液性腺癌患者202例，应用组织芯片和免疫组化法检测肿瘤组织中Pax2和cyclin D1蛋白的表达，分析其与患者临床病理特征及预后的关系。 结果： 202例卵巢浆液性腺癌患者中，Pax2蛋白的阳性率为24.8%(50/202)，cyclin D1蛋白的阳性率为25.2%(51/202)。Pax2和cyclin D1在不同年龄、临床分期和病理分级的卵巢浆液性腺癌患者中的表达水平差异均无统计学意义(均P>0.05)。Pax2阴性患者的中位生存时间为53个月，中位无进展生存时间为29个月。Pax2阳性患者的中位生存时间为66个月，中位无进展生存时间为33个月。Pax2阴性和阳性患者的中位生存时间差异有统计学意义 (χ(2)＝4.06，P＝0.04)，Pax2阴性和阳性患者的中位无进展生存时间差异无统计学意义(χ(2)＝2.43，P＝0.11)。cyclin D1阴性患者的中位生存时间为62个月，中位无进展生存时间为30个月。cyclin D1阳性患者的中位生存时间为48个月，中位无进展生存时间为22个月。cyclin D1阴性和阳性患者的中位生存时间差异有统计学意义 (χ(2)＝4.71，P＝0.03)，cyclin D1阴性和阳性患者的中位无进展生存时间差异无统计学意义(χ(2)＝0.59，P＝0.41)。多因素分析显示，Pax2表达为影响卵巢浆液性腺癌患者预后的独立因素(RR为0.597，95%CI为0.371～0.962, P<0.034)。 结论： Pax2和cyclin D1表达与晚期卵巢浆液性腺癌患者的预后有关，Pax2为影响晚期卵巢浆液性腺癌患者预后的独立因素。.

[Abstract] [Full Text] [Related] [New Search]